| Prev Close | 1.16 |
| Day Low/High | 1.14 / 1.20 |
| 52 Wk Low/High | 1.09 / 3.10 |
Trevena, Inc. (TRVN)
1.14
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 164.51B |
| Market Cap | 190.83M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
The January Effect Is on Time This Year
I continue to believe that biotech and biopharma stocks will outperform in 2018.
Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers
The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.
3 Beaten-Down Biotechs That Should Head Up
Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.
2 Questions From the Biotech Mailbag
A look at how lawsuits and FDA changes could impact the industry.
Why Cara Therapeutics Is Up, Trevena Down
Readers want to know what to do with the two biotech names, which are headed in opposite directions.
What You Should Know About Trevena's New Painkiller
Trevena's oliceridine seeks to provide the pain relief of morphine with less side effects.
Get Addicted to Trevena
This small-cap biopharma has a solid pipeline and a sound balance sheet.
Cara Therapeutics on a Run
Not much change in the market since our last update. The S&P 500 and Dow are down, and the NASDAQ is having a nice day. Longtime favorite Cara Therapeutics continues its huge run, up another 20% plus today. But I can't find any new news to support t...
Market Advantage Shifts to the Pessimists
Buyers don't have much staying power.
Neither Bears Nor Bulls Can Rejoice
The bears had a good opportunity early on but did nothing with it, though buyers gained little traction.
The Bulls Have No Place to Hide
The bears are locked and loaded.
Bulls Steadfast, but Market Players Skittish
Not a big day of gains, but there is underlying support.
Say What You Will, Bears: Price Action Is Good
Intraday dip buying is a good sign.
Trevena: Friday's Small-Cap Focus Stock
Small-cap biotech offers a big, promising pipeline.
Market Has a Mood Swing to the Upside
Gloom is gone as likelihood of Fed rate hike fades.
Flow of Bad News Pours Over Market
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
Late Buying Spurs Intraday Bounce
Mood improves, but there are still lots of reasons to worry.
'Sell the News' Reaction Is Quite Logical
After poor close on Thursday, market trends down all day.
Cutting Through the Fed Confusion
So where does the market go from here?
Market Gets Ahead of Fed Action
Today's strong action complicates the situation.
Sneaky Market Strength Has Nothing to Do With the Fed
Anxiety over being left behind is building.
Yawning All the Way to the Fed Decision
We have a few more days of this slow trading, and it is unlikely to change much.
Ugly Friday Finishes Off Last Week's Hope
Signs of support on the S&P, but there is a lot of uncertainty.
